Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative dataEric I. Benchimol, Teresa To, Astrid Guttmann et al.|Gut|2009Cited by 411
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Matthew T. Duvernay, Metin Kurtoğlu et al.|The Lancet Neurology|2023Cited by 255
Myasthenia gravis: the role of complement at the neuromuscular junctionJames F. Howard|Annals of the New York Academy of Sciences|2017Cited by 196
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort studyPushpa Narayanaswami, Gilles Hoffmann, Donald B. Sanders et al.|The Lancet Neurology|2024Cited by 53
Addressing Outcome Measure Variability in Myasthenia Gravis Clinical TrialsJeffrey T. Guptill, Henry J. Kaminski, Michael Benatar et al.|Neurology|2023Cited by 26